Black Diamond Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BDTX | BBOT | KZIA | CRDF | AVBP | KROS | |
|---|---|---|---|---|---|---|
| Market cap | 108.87M | 184.40M | 92.33M | 67.60M | 665.16M | 214.73M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.7 | -0.8 | -1,473.8 | -1.6 | -3.6 | -1.6 |
| Price/book | 1.1 | 0.6 | 2.8 | 2.2 | 1.8 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −53.23% | −81.29% | +7.73% | −61.33% | −26.64% | −30.80% |
| Today | +4.97% | −0.86% | 0.00% | +0.67% | +3.61% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BDTX news ›Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy
Seeking Alpha - I am downgrading Black Diamond Therapeutics from Strong Buy to 'Buy' due to slower-than-expected phase 3 initiation for silevertinib in 1st-line non-classical EGFRm NSCLC. - BDTX's sileverti
Black Diamond Therapeutics downgraded to Buy on slower phase 3 start for lung cancer drug silevertinib.
Black Diamond Therapeutics (BDTX) has been downgraded from Strong Buy to Buy due to a slower-than-expected start of phase 3 trials for its lung cancer drug silevertinib, targeting non-classical EGFR mutations in NSCLC. Despite this, phase…
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Lifted to “Hold” by Wall Street Zen
Posted by Mitch Edgeman on Oct 25th, 2026 Wall Street Zen upgraded shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street…
Black Hawk Acquisition Corporation Announces Redemption Results in Connection With Its Business Combination With Vesicor Therapeutics Inc.
About the Business Combination On April 26, 2025, Vesicor Therapeutics, Inc. entered into the Business Combination Agreement, as amended. Upon closing of the Business Combination, the combined company is expected to become a publicly…
Comparing Absci (NASDAQ:ABSI) & Black Diamond Therapeutics (NASDAQ:BDTX)
Posted by Danessa Lincoln on Oct 13th, 2026 Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) and Absci (NASDAQ:ABSI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the…
More from 1 other outlet
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
Dianthus Therapeutics (Nasdaq: DNTH) was selected for Fortune’s 2026 Best Workplaces in BioPharma list, marking its first appearance on the list. It ranked among the top 30 small- and medium-sized biotechnology and pharmaceutical companies…
Entrada Therapeutics (NASDAQ:TRDA) and Black Diamond Therapeutics (NASDAQ:BDTX) Critical Analysis
Posted by Defense World Staff on Oct 8th, 2026 Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap healthcare companies, but which is the better business?…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com3
- defenseworld.net2
- mycarrollcountynews.com1
- pluang.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.